To include your compound in the COVID-19 Resource Center, submit it here.

Gamma secretase inhibitor: Phase II data

Based on data from the double-blind, placebo-controlled, international Phase II CN156-013 trial in 209 patients with mild to moderate AD, Bristol-Myers said BMS-708163 at doses of <100 mg/day provide a "potential therapeutic window" for evaluation in Phase III studies. At those doses, the compound demonstrated

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE